0.10Open0.10Pre Close0 Volume58 Open Interest18.50Strike Price0.00Turnover0.00%IV-0.49%PremiumNov 15, 2024Expiry Date0.19Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma183.10Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
$Nxu Inc (NXU.US)$ grab some on your way out.
After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.
No comment yet